

Science News

from research organizations

New blood test useful to detect people at risk of developing Alzheimer's disease

Date: April 6, 2018

Source: EMBO

Summary: Alzheimer's disease is thought to begin long before patients show typical symptoms like memory loss. Scientists have now developed a blood test for Alzheimer's disease and found that it can detect early indicators of the disease long before the first symptoms appear in patients. The blood test would thus offer an opportunity to identify those at risk and may thereby open the door to new avenues in drug discovery.

Share:      

FULL STORY

There is, as yet, no cure for Alzheimer's disease. It is often argued that progress in drug research has been hampered by the fact that the disease can only be diagnosed when it is too late for an effective intervention. Alzheimer's disease is thought to begin long before patients show typical symptoms like memory loss. Scientists have now developed a blood test for Alzheimer's disease and found that it can detect early indicators of the disease long before the first symptoms appear in patients. The blood test would thus offer an opportunity to identify those at risk and may thereby open the door to new avenues in drug discovery. The research is published today in *EMBO Molecular Medicine*.

One of the hallmarks of Alzheimer's disease is the accumulation of amyloid-beta plaques in the patient's brain. The blood test, developed by Klaus Gerwert and his team at Ruhr University Bochum, Germany, works by measuring the relative amounts of a pathological and a healthy form of amyloid- β in the blood. The pathological form is a misfolded version of this molecule and known to initiate the formation of toxic plaques in the brain. Toxic amyloid-beta molecules start accumulating in the patients' body 15-20 years before disease onset. In the present study, Gerwert and colleagues from Germany and Sweden addressed whether the blood test would be able to pick up indications of pathological amyloid-beta in very early phases of the disease.

The researchers first focused on patients in the early, so called prodromal stages of the disease from the Swedish BioFINDER cohort conducted by Oskar Hanson. They found that the test reliably detected amyloid-beta alterations in the blood of participants with mild cognitive impairment that also showed abnormal amyloid deposits in brain scans.

In a next step, Gerwert and colleagues investigated if their assay was able to detect blood changes well ahead of disease onset. They used data from the ESTHER cohort study, which Hermann Brenner started in 2000 at DKFZ, comparing blood samples of 65 participants that were later in the follow-up studies diagnosed with Alzheimer's disease with 809 controls. The assay was able to detect signs of the disease on average eight years before diagnosis in individuals without clinical symptoms. It correctly identified those with the disease in almost 70% of the cases, while about 9% of true negative subjects would wrongly be detected as positive. The overall diagnostic accuracy was 86%.

Currently available diagnostic tools for Alzheimer's disease either involve expensive positron emission tomography (PET) brain scans, or analyze samples of cerebrospinal fluid that are extracted via lumbar puncture. The researchers suggest that their blood test serves as a cheap and simple option to pre-select individuals from the general population for further testing by these more invasive and costly methods to exclude the falsely positive subjects. The blood test developed by Gerwert and colleagues uses a technology called immuno-infrared sensor to measure distribution of pathological and healthy structures of amyloid-beta. The pathological amyloid-beta structure is rich in a sticky, sheet-like folding pattern that makes it prone to aggregation, while the healthy structure is not. The two structures absorb infrared light at a different frequency, allowing the blood test to determine the ratio of healthy to pathological amyloid-beta in the sample.

The blood test will be extended to Parkinson disease by measuring another disease biomarker -- alpha-synuclein -- instead of amyloid-beta.

Story Source:

Materials provided by **EMBO**. *Note: Content may be edited for style and length.*

Journal Reference:

1. Andreas Nabers, Laura Perna, Julia Lange, Ute Mons, Jonas Schartner, Jörn Güldenhaupt, Kai-Uwe Saum, Shorena Janelidze, Bernd Holleczek, Dan Rujescu, Oskar Hansson, Klaus Gerwert, Hermann Brenner. **Amyloid blood biomarker detects Alzheimer's disease**. *EMBO Molecular Medicine*, 2018; e8763 DOI: 10.15252/emmm.201708763

Cite This Page:

MLA	APA	Chicago
-----	-----	---------

EMBO. "New blood test useful to detect people at risk of developing Alzheimer's disease." ScienceDaily. ScienceDaily, 6 April 2018. <www.sciencedaily.com/releases/2018/04/180406100535.htm>.

RELATED STORIES

Toward an Early Alzheimer's Test

Aug. 24, 2017 — Researchers have demonstrated the promise of an early blood test for Alzheimer's disease. The results suggest that Alzheimer's can be detected even before the onset of symptoms in persons at genetic ... **read more »**

Significant Step Towards Blood Test for Alzheimer's

July 7, 2014 — Scientists have identified a set of 10 proteins in the blood which can predict the onset of Alzheimer's, marking a significant step towards developing a blood test for the disease. A blood test could ... **read more »**

How Alzheimer's Blood Test Could Be First Step in Developing Treatments to Halt or Slow Disease

May 23, 2014 — A blood test has the potential to predict Alzheimer's disease before patients start showing symptoms, researchers have reported. Now they expand upon this groundbreaking research and discuss why it ... **read more »**

Blood Test to Diagnose Alzheimer's in Earliest Stage?

May 29, 2013 — Blood offers promise as a way to detect Alzheimer's disease at its earliest onset, researchers say. They envision a test that would detect distinct metabolic signatures in blood plasma that are ... **read more »**

FROM AROUND THE WEB

Below are relevant articles that may interest you. ScienceDaily shares links and proceeds with scholarly publications in the TrendMD network.

Blood test detects Alzheimer's before symptoms appear

Tim Newman, Medical News Today

Blood screening tests could predict Alzheimer's disease

Hannah Nichols, Medical News Today

How an eye test could detect Alzheimer's

Honor Whiteman, Medical News Today

Algorithm could predict Alzheimer's risk years before symptoms occur

Honor Whiteman, Medical News Today

Alzheimer's: new ultrasound technique 'restores memory' in mice

Honor Whiteman, Medical News Today

Red meat may raise Alzheimer's risk

Medical News Today

Alzheimer's: Protecting 'powerhouse' of cells may fuel new treatment

Catharine Paddock PhD, Medical News Today

Alzheimer's holds science at bay

Tom Siegfried, Knowable Magazine

Powered by

Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

 Email Newsletters

 RSS Feeds

Follow Us

Keep up to date with the latest news from ScienceDaily via social networks:

 Facebook

 Twitter

 Google+

 LinkedIn

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

 Leave Feedback

 Contact Us

[About This Site](#) | [Editorial Staff](#) | [Awards & Reviews](#) | [Contribute](#) | [Advertise](#) | [Privacy Policy](#) | [Terms of Use](#)

Copyright 2018 ScienceDaily or by other parties, where indicated. All rights controlled by their respective owners. Content on this website is for information only. It is not intended to provide medical or other professional advice. Views expressed here do not necessarily reflect those of ScienceDaily, its staff, its contributors, or its partners.

Financial support for ScienceDaily comes from advertisements and referral programs, where indicated.